Markets:

Overview

News

Currencies

International

Treasuries

Halozyme Therapeutics, Inc. - Common Stock (NQ:HALO)

102.88 -0.24 (-0.23%)

Streaming Delayed Price Updated: 3:41 PM EDT, Aug 10, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Halozyme Therapeutics, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 8 9

...

13 14 Next >

What 7 Analyst Ratings Have To Say About Halozyme Therapeutics ↗

August 18, 2025

Via Benzinga

HALOZYME THERAPEUTICS INC (NASDAQ:HALO) – A Top Pick for Affordable Growth Investors ↗

August 15, 2025

HALOZYME THERAPEUTICS (HALO) offers affordable growth with strong revenue, EPS expansion, and undervalued metrics, blending value and growth investing principles.

Via Chartmill

What Does the Market Think About Halozyme Therapeutics? ↗

August 07, 2025

Via Benzinga

HALOZYME THERAPEUTICS INC (NASDAQ:HALO) Fits Louis Navellier’s High-Growth Stock Criteria ↗

August 06, 2025

Louis Navellier’s *The Little Book That Makes You Rich* outlines 8 key factors for identifying high-growth stocks like HALOZYME THERAPEUTICS (HALO), which excels in earnings, sales, margins, and ROE....

Via Chartmill

Halozyme (HALO) Q2 EPS Jumps 69% ↗

August 05, 2025

Via The Motley Fool

Topics Intellectual Property

Earnings Scheduled For August 5, 2025 ↗

August 05, 2025

Via Benzinga

Earnings Outlook For Halozyme Therapeutics ↗

August 04, 2025

Via Benzinga

What's Driving the Market Sentiment Around Halozyme Therapeutics? ↗

May 28, 2025

Via Benzinga

Price Over Earnings Overview: Halozyme Therapeutics ↗

May 28, 2025

Via Benzinga

HALOZYME THERAPEUTICS INC (NASDAQ:HALO) Shows Strong Growth Momentum and Technical Breakout Potential ↗

July 30, 2025

HALOZYME THERAPEUTICS INC (HALO) shows strong earnings growth, rising profit margins, and bullish technicals, making it a high-growth momentum stock to watch.

Via Chartmill

Halozyme Therapeutics Inc (NASDAQ:HALO) Stands Out as a Strong Undervalued Stock with Solid Fundamentals ↗

July 25, 2025

Halozyme Therapeutics (HALO) is an undervalued biotech stock with strong fundamentals, low P/E ratios, high profitability, and solid growth potential, making it a compelling pick for value investors.

Via Chartmill

$1000 Invested In This Stock 15 Years Ago Would Be Worth This Much Today ↗

July 22, 2025

Via Benzinga

HALOZYME THERAPEUTICS INC (NASDAQ:HALO) - A Strong Contender in Affordable Growth Stocks ↗

July 21, 2025

HALOZYME THERAPEUTICS (NASDAQ:HALO) shows strong growth, solid profitability, and reasonable valuation, making it an interesting affordable growth stock in the biotech sector.

Via Chartmill

Here's How Much You Would Have Made Owning Halozyme Therapeutics Stock In The Last 15 Years ↗

July 07, 2025

Via Benzinga

HALOZYME THERAPEUTICS INC (NASDAQ:HALO) - A Strong Candidate for Affordable Growth Investors ↗

June 28, 2025

HALOZYME THERAPEUTICS (NASDAQ:HALO) offers strong growth, solid profitability, and reasonable valuation, making it a standout in affordable growth investing.

Via Chartmill

HALOZYME THERAPEUTICS INC (NASDAQ:HALO) – A Biotech Stock With Strong Fundamentals and Attractive Valuation ↗

June 25, 2025

HALOZYME THERAPEUTICS (NASDAQ:HALO) offers a rare mix of strong growth, profitability, and financial health at an attractive valuation, making it a standout in the biotech sector.

Via Chartmill

HALOZYME THERAPEUTICS INC (NASDAQ:HALO) – A Strong Growth Stock with Technical Breakout Potential ↗

June 17, 2025

HALOZYME THERAPEUTICS INC (NASDAQ:HALO) shows strong growth fundamentals and a potential technical breakout, making it a stock to watch in the biotech sector.

Via Chartmill

Here's How Much $100 Invested In Halozyme Therapeutics 15 Years Ago Would Be Worth Today ↗

June 12, 2025

Via Benzinga

HALOZYME THERAPEUTICS INC (NASDAQ:HALO) - A Strong Candidate for Affordable Growth Investors ↗

June 07, 2025

HALOZYME THERAPEUTICS (NASDAQ:HALO) offers strong growth, solid profitability, and an attractive valuation, making it a standout in the biotech sector for investors seeking affordable growth...

Via Chartmill

Here's How Much You Would Have Made Owning Halozyme Therapeutics Stock In The Last 5 Years ↗

June 04, 2025

Via Benzinga

HALOZYME THERAPEUTICS INC (NASDAQ:HALO) – A Biotech Stock With Strong Fundamentals and Attractive Valuation ↗

June 03, 2025

HALOZYME THERAPEUTICS (NASDAQ:HALO) offers strong profitability, financial health, and growth at an attractive valuation, making it a potential value opportunity in biotech.

Via Chartmill

Benzinga's 'Stock Whisper' Index: 5 Stocks Investors Secretly Monitor But Don't Talk About Yet ↗

May 24, 2025

The Benzinga Stock Whisper Index highlights five stocks seeing increased interest from readers during the week and a look at what's drivin the interest.

Via Benzinga

HALOZYME THERAPEUTICS INC (NASDAQ:HALO) - A Strong Candidate for Affordable Growth Investors ↗

May 17, 2025

HALOZYME THERAPEUTICS (NASDAQ:HALO) offers strong growth, solid profitability, and an attractive valuation, making it a standout in the biotech sector for investors seeking affordable growth...

Via Chartmill

Evolv Technologies, Quantum Computing, ACADIA Pharmaceuticals And Other Big Stocks Moving Higher On Friday ↗

May 16, 2025

Via Benzinga

12 Health Care Stocks Moving In Tuesday's After-Market Session ↗

May 13, 2025

Via Benzinga

Crude Oil Gains 3%; US Inflation Eases In April ↗

May 13, 2025

Via Benzinga

Topics Economy

12 Health Care Stocks Moving In Tuesday's Intraday Session ↗

May 13, 2025

Via Benzinga

There are notable gap-ups and gap-downs in today's session. ↗

May 13, 2025

Let's delve into the US markets on Tuesday and uncover the stocks that are experiencing notable gaps in today's session. Below, you'll find the gap up and gap down stocks.

Via Chartmill

Top Biotech Halozyme Undercuts Its Breakout On Bad Medicare News ↗

May 13, 2025

It's biggest product will be up for price negotiations under the Inflation Reduction Act much sooner than expected.

Via Investor's Business Daily

Topics Economy Government

HALOZYME THERAPEUTICS INC (NASDAQ:HALO) – An Undervalued Biotech Stock Worth Watching ↗

May 13, 2025

HALOZYME THERAPEUTICS (NASDAQ:HALO) is an undervalued biotech stock with strong profitability, financial health, and growth potential, making it a compelling pick for value investors.

Via Chartmill

< Previous 1 2 3 4 5 6 7 8 9

...

13 14 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.